Acasti Pharma/ACST

$2.87

-6.51%
-
1D1W1MYTD1YMAX

About Acasti Pharma

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

Ticker

ACST

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Prashant Kohli

Employees

32

Headquarters

Laval, Canada

Acasti Pharma Metrics

BasicAdvanced
$26.98M
Market cap
-
P/E ratio
-$5.06
EPS
1.55
Beta
-
Dividend rate
$26.98M
1.5513
$3.84
$1.72
26.35K
15.189
-14.38%
-40.18%
-48.05%
-41.3%
0.417
1.75
-107.98%

What the Analysts think about Acasti Pharma

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
109.76% upside
High $6.02
Low $6.02
$2.87
Current price
$6.02
Average price target

Acasti Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
-
Net income
$-2.3M
-28.13%
Profit margin
0%
-

Acasti Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.4%
QuarterlyAnnual
Q4 23
Q3 24
Q4 24
Actual
-CA$3.90
-CA$0.30
-
Expected
-CA$0.84
-CA$0.31
-CA$0.48
Surprise
364.29%
-3.4%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Acasti Pharma stock?

Acasti Pharma (ACST) has a market cap of $26.98M as of April 23, 2024.

What is the P/E ratio for Acasti Pharma stock?

The price to earnings (P/E) ratio for Acasti Pharma (ACST) stock is 0 as of April 23, 2024.

Does Acasti Pharma stock pay dividends?

No, Acasti Pharma (ACST) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Acasti Pharma dividend payment date?

Acasti Pharma (ACST) stock does not pay dividends to its shareholders.

What is the beta indicator for Acasti Pharma?

Acasti Pharma (ACST) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Acasti Pharma stock price target?

The target price for Acasti Pharma (ACST) stock is $6.03, which is 111.58% above the current price of $2.85. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Acasti Pharma stock

Buy or sell Acasti Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing